ExCell Bio Closes ¥100M Yuan in A New Round

According to VCBeat, ExCell Bio has completed a new round of nearly 100 million yuan in financing. This round of financing was led by Yonghua Investment, followed by Zhongguancun Development Qihang Innovation Investment Fund, Suzhou Yajie Angel Investment, and Yao Kun Technology. 

Excell Biotech founded in 2013, which originated from the well-known brand--gene times, is one of the largest suppliers of biological reagents and consumables in China. Many of the company's products fill the domestic gap. Our company is the leading enterprise of the core raw materials in the upstream of China's biomedical industry, and also the first member unit of the International Association of Serum Industry, the national high-tech enterprise, the engineering technology research center of cell therapy culture medium and gene detection reagent in Suzhou, the enterprise of reaching the standard of the quality of serum production in China, and the most potential investment in Suzhou in 2017.

This round of financing is mainly used to build a serum-free culture medium GMP production workshop, further expand overseas serum factories, increase production capacity, accelerate the construction of overseas marketing networks, and focus on the development direction and goals of Ekosai Biology in the next three to five years, and enhance the company's core competition force.

Founded in 2019, Beijing-based Zhongguancun Development Qihang Innovation Investment Fund, and is under the management of Beijing Qihang Investment Management Co., Ltd., with a registered capital of 503 million yuan.